15 April 2015 in American Journal of Physiology-Renal Physiology
Glucagon-like peptide (GLP)-1 has a range of extrapancreatic effects, including renal effects. The mechanisms are poorly understood, but GLP-1 receptors have been identified in the kidney. However, the exact cellular localization of the renal receptors is poorly described. The aim of the present study was to localize renal GLP-1 receptors and describe GLP-1-mediated effects on the renal vasculature. We hypothesized that renal GLP-1 receptors are located in the renal microcirculation and that activation of these affects renal autoregulation and increases renal blood flow. In vivo autoradiography using 125I-labeled GLP-1, 125I-labeled exendin-4 (GLP-1 analog), and 125I-labeled exendin 9–39 (GLP-1 receptor antagonist) was performed in rodents to localize specific GLP-1 receptor binding. GLP-1-mediated effects on blood pressure, renal blood flow (RBF), heart rate, renin secretion, urinary flow rate, and Na+ and K+ excretion were investigated in anesthetized rats. Effects of GLP-1 on afferent arterioles were investigated in isolated mouse kidneys. Specific binding of 125I-labeled GLP-1, 125I-labeled exendin-4, and 125I-labeled exendin 9–39 was observed in the renal vasculature, including afferent arterioles. Infusion of GLP-1 increased blood pressure, RBF, and urinary flow rate significantly in rats. Heart rate and plasma renin concentrations were unchanged. Exendin 9–39 inhibited the increase in RBF. In isolated murine kidneys, GLP-1 and exendin-4 significantly reduced the autoregulatory response of afferent arterioles in response to stepwise increases in pressure. We conclude that GLP-1 receptors are located in the renal vasculature, including afferent arterioles. Activation of these receptors reduces the autoregulatory response of afferent arterioles to acute pressure increases and increases RBF in normotensive rats.
1 May 2010 in American Journal of Physiology-Regulatory, Integrative and Comparative Physiology
Connexins (Cxs) are widely-expressed proteins that form gap junctions in most organs, including the kidney. In the renal vasculature, Cx37, Cx40, Cx43, and Cx45 are expressed, with predominant expression of Cx40 in the endothelial cells and Cx45 in the vascular smooth muscle cells. In the tubules, there is morphological evidence for the presence of gap junction plaques only in the proximal tubules. In the distal nephron, Cx30, Cx30.3, and Cx37 are expressed, but it is not known whether they form gap junctions connecting neighboring cells or whether they primarily act as hemichannels. As in other systems, the major function of Cxs in the kidney appears to be intercellular communication, although they may also form hemichannels that allow cellular secretion of large signaling molecules. Renal Cxs facilitate vascular conduction, juxtaglomerular apparatus calcium signaling, and tubular purinergic signaling. Accordingly, current evidence points to roles for these Cxs in several important regulatory mechanisms in the kidney, including the renin angiotensin system, tubuloglomerular feedback, and salt and water reabsorption. At the systemic level, renal Cxs may help regulate blood pressure and may be involved in hypertension and diabetes.
28 November 2007 in Hepatology
Patients with advanced cirrhosis and ascites are characterized by circulatory dysfunction with splanchnic vasodilatation and renal vasoconstriction, which often lead to ascites. The vasoconstrictor terlipressin improves renal function in hepatorenal syndrome (HRS). The aim of this study was to evaluate if terlipressin also improves renal function in patients with ascites without HRS. Twenty-three patients with cirrhosis participated; 15 with nonrefractory ascites were randomized to either terlipressin (N group, n = 11) or a placebo (P group, n = 4), and 8 had refractory ascites and received terlipressin (R group). The glomerular filtration rate (GFR), sodium clearance (
C
Na), lithium clearance (
C
Li), osmolal clearance (
C
Osm), and urine sodium concentration (
U
Na) were assessed before and after the injection of 2 mg of terlipressin or the placebo. GFR increased in the N group (69 ± 19 versus 92 ± 25 mL/min,
P
< 0.005) and in the R group (31 ± 19 versus 41 ± 31 mL/min,
P
< 0.05) after terlipressin. In the N group, terlipressin induced an increase in
C
Na (0.89 ± 0.21 versus 1.52 ± 1.45 mL/min,
P
< 0.05),
C
Li (17.3 ± 8.9 versus 21.5 ± 11.6 mL/min,
P
< 0.05), and
C
Osm (2.10 ± 0.81 versus 3.06 ± 2.0 mL/min,
P
< 0.05). In the R group, terlipressin induced an increase in
C
Na (0.11 ± 0.18 versus 0.35 ± 0.40 mL/min,
P
< 0.05) and
C
Li (5.5 ± 4.2 versus 9.5 ± 8.55 mL/min,
P
< 0.05).
U
Na increased in both groups after terlipressin (
P
< 0.005). Plasma norepinephrine (
P
< 0.05) and renin (
P
< 0.05) decreased after terlipressin. All parameters remained unchanged after the placebo.
Conclusion:
The vasopressin 1 receptor agonist terlipressin improves renal function and induces natriuresis in patients with cirrhosis and ascites without HRS. Vasoconstrictors may represent a novel future treatment modality for these patients. (Hepatology 2007.)
1 June 2006 in Journal of Molecular and Cellular Cardiology
12 May 2003 in Journal of Cardiovascular Electrophysiology